Rybelsus (Semaglutide): Comprehensive Patient Information
Basic Product Information
| International Non-Proprietary Name (INN) | Semaglutide |
| Australia Brand Names | Rybelsus |
| Anatomical Therapeutic Chemical (ATC) Code | A10BJ06 |
| Available Forms & Strengths | Tablets: 3 mg, 7 mg, 14 mg |
| Manufacturers | Novo Nordisk Pharmaceuticals Pty Ltd |
| Prescription Status | Prescription only (Schedule 4) in Australia |
Mechanism of Action
For Patients: Rybelsus contains semaglutide, a medicine that helps lower blood sugar in adults with type 2 diabetes. It mimics a natural hormone in your body (GLP-1) that helps regulate blood sugar, curbs appetite, and slows down the movement of food from the stomach.
For Healthcare Professionals: Semaglutide is a human GLP-1 receptor agonist. It increases insulin secretion and decreases glucagon release in a glucose-dependent manner, delays gastric emptying, and promotes satiety, contributing to glycaemic control and weight reduction.
Pharmacokinetics
- Absorption: Oral semaglutide has an absolute bioavailability of 0.4-1.0%, with peak plasma levels reached about 1 hour after dosing on an empty stomach.
- Metabolism: Metabolised by proteolytic cleavage of the peptide backbone and β-oxidation of the fatty acid side chain.
- Elimination: Excreted via urine and feces; the half-life is approximately 1 week, supporting once-daily dosing.
- Duration of Action: Extended; maintains therapeutic levels with once-daily dosing.
Use in Everyday Life and Best Practices
- Recommended for: Adults with type 2 diabetes mellitus when diet, exercise, and/or other medications alone do not provide adequate glycaemic control.
- How to Use: Swallow the tablet whole with a small amount of water (up to 120 mL) upon waking, at least 30 minutes before eating or drinking or taking other oral medicines.
- Australian Context: Fits well with general dietary and lifestyle recommendations for Australians with diabetes—emphasising low added sugar, balanced meals, and regular physical activity.
Dosing in the Morning vs Evening
- Morning Dosing: Strongly recommended. Rybelsus should be taken in the morning after waking up, as food, drinks, and other medicines can affect how well your body absorbs semaglutide.
- Evening Dosing: Not generally advised due to increased risk of inconsistent absorption if food or other activities follow.
- Tips for Regularity: Take at the same time every day to develop a habit, reducing missed doses.
Taking with Food or on an Empty Stomach
- Best Absorption: Take Rybelsus with a sip of water (no more than 120 mL) at least 30 minutes before breakfast or any other medicines.
- Meals & Absorption: Eating sooner or taking it with a larger amount of water can significantly reduce effectiveness.
- Australian Diet: If you enjoy a typical Australian breakfast (like cereal, toast, tea, or coffee), make sure to have Rybelsus first, and wait at least 30 minutes before eating.
Interaction Warnings
| Interaction Type | Examples | Advice |
| Medications | Insulin, sulfonylureas, warfarin | May increase risk of hypoglycaemia or affect warfarin levels—monitor blood sugar or INR. |
| Dietary | High-fat meals, large amounts of liquid | Reduce absorption—follow dosing instructions carefully. |
| Alcohol | Beer, wine, spirits | May increase risk of low blood sugar—moderation is recommended. |
| Other Oral Medicines | All oral medications | Take Rybelsus first, then wait at least 30 minutes before any other tablets or food. |
Indications
| Indication | Official Status | Notes |
| Type 2 diabetes mellitus | Approved (TGA) | For adults inadequately controlled by diet and exercise, as monotherapy or with other glucose-lowering drugs |
| Weight management | Off-label | May be considered in patients with obesity & type 2 diabetes—seek specialist advice |
| Prevention of cardiovascular events | Expanding evidence | Shown to reduce risk in type 2 diabetes with established cardiovascular disease |
Dosing According to Clinical Indication
| Patient Population | Starting Dose | Titration | Maximum Dose | Notes |
| Adults (Type 2 Diabetes) | 3 mg once daily | After 30 days, increase to 7 mg; may increase to 14 mg after further 30 days if needed | 14 mg once daily | Do not split or crush tablets; only one tablet per day |
| Elderly | Same as adult dose | Monitor for increased GI side effects, especially in frail patients | 14 mg once daily | No dose adjustment required for age alone |
| Paediatric (<18 years) | Not recommended | - | - | Safety and efficacy not established |
| Renal or hepatic impairment | Start with caution | Monitor patient closely | 14 mg once daily | No dose adjustment but increased monitoring |
Safety Profile & Side Effects
| Frequency | Side Effects | Notes |
| Common (≥1/10 patients) | Nausea, diarrhoea, vomiting, decreased appetite, abdominal pain, constipation | Gastrointestinal symptoms usually diminish over time |
| Occasional (1/100–1/10) | Indigestion, heartburn, fatigue, dizziness, hypoglycaemia (with sulfonylureas or insulin) | Monitor blood sugar if taking with other diabetes medication |
| Rare (<1/1000) | Pancreatitis, allergic reactions, changes in vision | Seek medical attention for severe or persistent symptoms |
| Serious | Pancreatitis, severe gastrointestinal symptoms, severe allergic reaction (anaphylaxis), worsening diabetic retinopathy | Seek urgent medical attention |
Guidelines for Proper Use (Australia-specific Advice)
- Rybelsus should be stored below 30°C—avoid leaving tablets in hot cars or direct sunlight.
- Take your tablet whole, with a small sip of water, first thing in the morning—do not split, crush, or chew the tablet.
- Wait at least 30 minutes before eating, drinking (besides water), or taking any other oral medicines.
- If you miss a dose, skip it and take your next dose at the usual time the next day. Do not take a double dose.
- Maintain regular follow-ups with your GP or diabetes educator; monitor blood sugar as instructed.
- Report any signs of severe or persistent abdominal pain, vomiting, or allergic reactions to your doctor immediately.
- Be alert for symptoms of low blood sugar if you take other diabetes medications.
Alternative Treatment Options
- SGLT2 Inhibitors (e.g., dapagliflozin, empagliflozin): Also available on the PBS; effective for blood sugar lowering and weight loss, may offer kidney/cardiac protection but with different side effect profile.
- DPP-4 Inhibitors (e.g., sitagliptin): Less effective for weight loss, generally well-tolerated but with milder efficacy.
- Metformin: Standard first-line agent for type 2 diabetes—well-tolerated, weight-neutral, widely subsidized.
- Other GLP-1 Agonists (e.g., Ozempic, Trulicity): Injectable forms of semaglutide or dulaglutide, similar mechanism but different mode of administration and dosing frequency.
- Sulfonylureas and Insulins: Effective but carry a higher risk for hypoglycaemia and weight gain compared to GLP-1 agonists.
Legal, Registration, and Reimbursement Status in Australia
- TGA Registration: Rybelsus is registered in Australia with the Therapeutic Goods Administration (TGA).
- PBS Status: As of mid-2024, Rybelsus is available on the Pharmaceutical Benefits Scheme (PBS) for eligible patients with type 2 diabetes. Restrictions apply; consult your GP or pharmacist for individual eligibility.
- Prescription Requirement: Schedule 4 (S4 - Prescription Only Medicine).
- Special Authority: An authority prescription may be required for PBS subsidy.
Latest Research & Clinical Guidance (2022–2025)
- Large trials (PIONEER studies) consistently show that oral semaglutide effectively improves HbA1c and supports weight loss in adults with type 2 diabetes (Davies et al., NEJM, 2022; Zinman et al., Lancet Diabetes Endocrinol, 2023).
- Real-world data and international guidelines highlight semaglutide’s cardiovascular benefits in patients with established cardiovascular disease, aligning with Australian Diabetes Society and RACGP recommendations.
- Ongoing studies (2024–2025) are investigating expanded indications, including use in weight management (without diabetes) and long-term cardiovascular outcomes.
Availability and Delivery
| Pack Size | Strength | Indicative PBS Price* | Delivery Time** | Availability |
| 30 tablets | 3 mg, 7 mg, 14 mg | $42.50 (PBS, general); $7.30 (concession) | Sydney: 1–2 days | In stock |
| 90 tablets | 7 mg, 14 mg | $122.20 (private) | Melbourne: 1–3 days | In stock |
| 60 tablets | Various | Varies (mix) | Brisbane/Perth: 2–4 days | On request |
*Prices as of June 2024 and may change.
**Delivery times are indicative for metro areas—rural deliveries may take longer.
FAQ – Frequently Asked Patient Questions
- Can I take Rybelsus with my other diabetes tablets?
Yes, but make sure to take Rybelsus first thing in the morning, then wait at least 30 minutes before any other oral medicines or breakfast. Monitor your blood sugar closely, especially if you also take insulin or sulfonylureas. - What if I forget to take a dose?
Skip the missed dose and continue as usual the next morning. Do not take a double dose to make up for a missed tablet. - Will Rybelsus help me lose weight?
Many patients experience some weight loss as a side effect. Rybelsus works by reducing appetite and food intake, but it is not a weight loss medicine on its own—healthy eating and regular activity remain important. - Are there long-term risks?
Rybelsus is well-studied for long-term safety. Some risks, such as gastrointestinal side effects and rare cases of pancreatitis, are known. Regular doctor reviews help ensure ongoing safety and effectiveness. - Is Rybelsus safe in pregnancy or breastfeeding?
No, it is not recommended for use in pregnancy or during breastfeeding. Ask your doctor about safer alternatives if you are pregnant or planning a pregnancy.
